Biomedicines,
Год журнала:
2024,
Номер
12(1), С. 202 - 202
Опубликована: Янв. 16, 2024
Peptide-functionalized
nanomedicine,
which
addresses
the
challenges
of
specificity
and
efficacy
in
drug
delivery,
is
emerging
as
a
pivotal
approach
for
cancer
therapy.
Globally,
remains
leading
cause
mortality,
conventional
treatments,
such
chemotherapy,
often
lack
precision
adverse
effects.
The
integration
peptides
into
nanomedicine
offers
promising
solution
enhancing
targeting
delivery
therapeutic
agents.
This
review
focuses
on
three
primary
applications
peptides:
cell-targeting
ligands,
building
blocks
self-assembling
nanostructures,
elements
stimuli-responsive
systems.
Nanoparticles
modified
with
improved
cells,
minimized
damage
to
healthy
tissues,
optimized
delivery.
versatility
self-assembled
peptide
structures
makes
them
an
innovative
vehicle
by
leveraging
their
biocompatibility
diverse
nanoarchitectures.
In
particular,
mechanism
cell
death
induced
novel
addition,
systems
enable
precise
release
response
specific
conditions
tumor
microenvironment.
use
not
only
augments
safety
treatments
but
also
suggests
new
research
directions.
this
review,
we
introduce
functionalization
methods
using
or
peptide-modified
nanoparticles
overcome
treatment
cancers,
including
breast
cancer,
lung
colon
prostate
pancreatic
liver
skin
glioma,
osteosarcoma,
cervical
cancer.
Nano TransMed,
Год журнала:
2024,
Номер
3, С. 100040 - 100040
Опубликована: Июнь 27, 2024
Currently,
cancer
is
the
leading
cause
of
death
globally.
In
absence
specific
treatment
and
early
diagnosis,
procedures
like
surgery,
chemotherapy,
radiation
therapy
are
often
used
to
manage
disease.
However,
these
approaches
fail
control
due
inefficacy,
nonspecific
distribution,
side
effects
drugs.
Anticancer
drugs
essential
in
reducing
cell
growth
helping
damage
those
cells.
severe
have
limited
bioavailability
their
distribution
throughout
body.
Therefore,
development
intelligent
drug
release
systems
essential.
Nanoparticle
delivery
promising
strategies
improve
therapeutic
efficacy
safety,
overcoming
challenges.
Among
systems,
a
natural
polysaccharide
called
chitosan,
derivative
chitin,
has
gained
considerable
attention
as
biocompatible,
biodegradable,
mucoadhesive
material
for
creating
nanoparticles.
Chitosan
nanoparticles
provide
several
advantages,
including
improved
stability,
cellular
uptake,
solubility
anticancer
drugs,
modulation
kinetics,
biodistribution.
Additionally,
chitosan
can
be
modified
on
surface
with
ligands
or
stimuli-responsive
moieties
achieve
targeted
cells
tissues.
This
review
explores
recent
advances
chitosan-based
nanoparticle
delivery,
efficacy,
applications
therapy.
Abstract
The
development
of
efficient
drug
delivery
systems
is
essential
for
improving
the
efficacy
and
safety
cancer
drugs,
particularly
aggressive
difficult‐to‐treat
cancers.
Covalent
organic
frameworks
(COFs)
are
emerging
as
innovative
porous
nanomaterials
in
(DDS),
due
to
their
unique
properties,
including
metal‐free
skeleton,
predetermined
structures
pore
geometries,
high
porosity,
large
surface
area,
facile
modification
potential,
good
biocompatibility.
These
characteristics
make
COFs
excellent
candidates
by
enhancing
loading
capacity
enabling
precise
encapsulation.
This
review
emphasizes
importance
donor‐acceptor‐based
COFs,
which
provide
channels
charge
transportation,
we
also
explore
how
π‐conjugated
skeleton
enhances
its
long‐acting
fluorescent
properties
facilitates
uptake
via
cell
endocytosis.
While
this
primarily
focuses
on
recent
advancements
COF‐based
targeted
DDS,
it
acknowledges
challenges
posed
diverse
geometries
materials
discusses
potential
solutions.
Further,
underlines
developing
future
carriers
that
can
successfully
specifically
target
cells,
treatment
efficiency
while
reducing
adverse
side
effects.
Expert Opinion on Drug Delivery,
Год журнала:
2024,
Номер
21(3), С. 495 - 511
Опубликована: Фев. 24, 2024
Breast
cancer
is
a
global
health
concern
that
demands
attention.
In
our
contribution
to
addressing
this
disease,
study
focuses
on
investigating
wireless
micro-device
for
intratumoral
drug
delivery,
utilizing
electrochemical
actuation.
Microdevices
have
emerged
as
promising
approach
in
field
due
their
ability
enable
controlled
injections
various
applications.
ABSTRACT
Signal
transducer
and
activator
of
transcription
3
(STAT3)
is
a
critical
factor
involved
in
multiple
physiological
pathological
processes.
While
STAT3
plays
an
essential
role
homeostasis,
its
persistent
activation
has
been
implicated
the
pathogenesis
various
diseases,
particularly
cancer,
bone‐related
autoimmune
disorders,
inflammatory
cardiovascular
neurodegenerative
conditions.
The
interleukin‐6/Janus
kinase
(JAK)/STAT3
signaling
axis
central
to
activation,
influencing
tumor
microenvironment
remodeling,
angiogenesis,
immune
evasion,
therapy
resistance.
Despite
extensive
research,
precise
mechanisms
underlying
dysregulated
disease
progression
remain
incompletely
understood,
no
United
States
Food
Drug
Administration
(USFDA)‐approved
direct
inhibitors
currently
exist.
This
review
provides
comprehensive
evaluation
STAT3's
health
disease,
emphasizing
involvement
cancer
stem
cell
maintenance,
metastasis,
inflammation,
drug
We
systematically
discuss
therapeutic
strategies,
including
JAK
(tofacitinib,
ruxolitinib),
Src
Homology
2
domain
(S3I‐201,
STATTIC),
antisense
oligonucleotides
(AZD9150),
nanomedicine‐based
delivery
systems,
which
enhance
specificity
bioavailability
while
reducing
toxicity.
By
integrating
molecular
mechanisms,
pathology,
emerging
interventions,
this
fills
knowledge
gap
STAT3‐targeted
therapy.
Our
insights
into
crosstalk,
epigenetic
regulation,
resistance
offer
foundation
for
developing
next‐generation
with
greater
clinical
efficacy
translational
potential.
Drug Resistance Updates,
Год журнала:
2023,
Номер
71, С. 101005 - 101005
Опубликована: Авг. 21, 2023
Multidrug
resistance
in
pancreatic
cancer
poses
a
significant
challenge
clinical
treatment.
Bufalin
(BA),
compound
found
secretions
from
the
glands
of
toads,
may
help
overcome
this
problem.
However,
severe
cardiotoxicity
thus
far
has
hindered
its
application.
Hence,
present
study
aimed
to
develop
cell
membrane-camouflaged
and
BA-loaded
polylactic-co-glycolic
acid
nanoparticle
(CBAP)
assess
potential
counter
chemoresistance
cancer.The
toxicity
CBAP
was
evaluated
by
electrocardiogram,
body
weight,
distress
score,
nesting
behavior
mice.
In
addition,
anticarcinoma
activity
underlying
mechanism
were
investigated
both
vitro
vivo.CBAP
significantly
mitigated
BA-mediated
acute
enhanced
sensitivity
several
drugs,
such
as
gemcitabine,
5-fluorouracil,
FOLFIRINOX.
Mechanistically,
directly
bound
nucleotide-binding
oligomerization
domain
containing
protein
2
(NOD2)
inhibited
expression
nuclear
factor
kappa-light-chain-enhancer
activated
B
cells.
This
inhibits
ATP-binding
cassette
transporters,
which
are
responsible
for
cells.Our
findings
indicate
that
NOD2.
Combining
with
standard-of-care
chemotherapeutics
represents
safe
efficient
strategy
treatment
cancer.
Nanomaterials,
Год журнала:
2023,
Номер
13(15), С. 2225 - 2225
Опубликована: Июль 31, 2023
Over
the
last
30
years,
diverse
types
of
nano-sized
drug
delivery
systems
(nanoDDSs)
have
been
intensively
explored
for
cancer
therapy,
exploiting
their
passive
tumor
targetability
with
an
enhanced
permeability
and
retention
effect.
However,
systemic
administration
has
aroused
some
unavoidable
complications,
including
insufficient
tumor-targeting
efficiency,
side
effects
due
to
undesirable
biodistribution,
carrier-associated
toxicity.
In
this
review,
recent
studies
advancements
in
intratumoral
nanoDDS
are
generally
summarized.
After
identifying
factors
be
considered
enhance
therapeutic
efficacy
administration,
experimental
results
on
application
various
therapies
discussed.
Subsequently,
reports
clinical
addressed
short.
Intratumoral
is
proven
its
versatility
tumor-specific
accumulation
agents
modalities.
Specifically,
it
can
improve
poor
bioavailability
by
increasing
concentration,
while
minimizing
effect
highly
toxic
restricting
normal
tissues.
expand
area
potent
ability
relieve
toxicities
nanoDDSs.
